- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06772623
Une étude visant à évaluer les événements indésirables, l'efficacité et la dose optimale du téisotuzumab adizutécan intraveineux (IV) en association avec le budigalimab IV chez des participants adultes atteints d'un CPNPC non épidermoïde avancé ou métastatique sans traitement préalable pour une maladie avancée et sans altérations génomiques exploitables
Une étude ouverte multicohorte de phase 1b/2 pour évaluer l'innocuité, l'efficacité et la dose optimale du téisotuzumab adizutecan en association avec le budigalimab dans le CPNPC non épidermoïde avancé ou métastatique sans traitement préalable pour une maladie avancée et sans altérations génomiques exploitables
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: ABBVIE CALL CENTER
- Numéro de téléphone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lieux d'étude
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Allemagne, 79106
- Recrutement
- Universitaetsklinikum Freiburg /ID# 268473
-
Heilbronn, Baden-Wurttemberg, Allemagne, 74078
- Recrutement
- Slk-Kliniken Heilbronn /ID# 269621
-
-
Bavaria
-
Augsburg, Bavaria, Allemagne, 86150
- Recrutement
- Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
-
Würzburg, Bavaria, Allemagne, 97080
- Recrutement
- Universitaetsklinikum Wuerzburg /ID# 275445
-
-
Hesse
-
Frankfurt am Main, Hesse, Allemagne, 60590
- Recrutement
- Universitaetsklinikum Frankfurt /ID# 268721
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Allemagne, 50937
- Recrutement
- Universitaetsklinikum Koeln /ID# 268489
-
Hemer, North Rhine-Westphalia, Allemagne, 58675
- Recrutement
- Lungenklinik Hemer /ID# 269779
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Allemagne, 23758
- Recrutement
- ohO Research GmbH /ID# 273060
-
-
Thuringia
-
Jena, Thuringia, Allemagne, 07747
- Recrutement
- Universitatsklinikum Jena /ID# 269700
-
-
-
-
-
Buenos Aires, Argentine, 1426
- Recrutement
- Centro Oncologico Korben /ID# 281460
-
Buenos Aires, Argentine, 1426
- Recrutement
- Fundacion Respirar /ID# 281039
-
-
Buenos Aires
-
Mar del Plata, Buenos Aires, Argentine, 7600
- Recrutement
- Clinca Colon /ID# 281465
-
-
Buenos Aires F.D.
-
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentine, 1426
- Recrutement
- Instituto Alexander Fleming /ID# 282704
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Australie, 2148
- Recrutement
- Blacktown Hospital /ID# 281588
-
-
Queensland
-
Townsville, Queensland, Australie, 4814
- Recrutement
- Townsville University Hospital /ID# 281498
-
-
South Australia
-
Elizabeth Vale, South Australia, Australie, 5112
- Recrutement
- Lyell Mcewin Hospital /ID# 281860
-
-
Victoria
-
Frankston, Victoria, Australie, 3199
- Recrutement
- Peninsula University Hospital /ID# 281824
-
-
-
-
-
Liège, Belgique, 4000
- Recrutement
- Groupe Sante CHC - Clinique du MontLegia /ID# 271760
-
-
Limburg
-
Hasselt, Limburg, Belgique, 3500
- Recrutement
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
-
-
Oost-Vlaanderen
-
Sint-Niklaas, Oost-Vlaanderen, Belgique, 9100
- Recrutement
- Vitaz /Id# 280187
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, Belgique, 8800
- Recrutement
- AZ-Delta. /ID# 272433
-
-
-
-
Region Metropolitana Santiago
-
Santiago, Region Metropolitana Santiago, Chili, 8330032
- Recrutement
- Pontificia Universidad Catolica De Chile /ID# 281594
-
Vitacura, Region Metropolitana Santiago, Chili, 7650027
- Recrutement
- Oncored /Id# 281108
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chili, 6900941
- Recrutement
- Fundacion Arturo Lopez Perez /ID# 281211
-
Santiago, Santiago Metropolitan, Chili, 7500713
- Recrutement
- Orlandi Oncologia /ID# 281132
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100021
- Recrutement
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350014
- Recrutement
- Fujian Province Cancer Hospital /ID# 269150
-
-
Guangxi
-
Liuzhou, Guangxi, Chine, 545006
- Recrutement
- Liuzhou People's hospital /ID# 269667
-
-
Henan
-
Zhengzhou, Henan, Chine, 450008
- Recrutement
- Henan Cancer Hospital /ID# 269668
-
-
Hubei
-
Wuhan, Hubei, Chine, 430022
- Recrutement
- Union Hospital - Tongji Medical College /ID# 272286
-
-
Hunan
-
Changsha, Hunan, Chine, 410013
- Recrutement
- Hunan Province Cancer Hospital /ID# 269679
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210008
- Recrutement
- Nanjing Drum Tower Hospital /ID# 269762
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330209
- Recrutement
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710061
- Recrutement
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200030
- Recrutement
- Shanghai Chest Hospital /ID# 269155
-
Shanghai, Shanghai Municipality, Chine, 200433
- Recrutement
- Shanghai Pulmonary Hospital /ID# 276397
-
-
Shanxi
-
Taiyuan, Shanxi, Chine, 030001
- Recrutement
- First Affiliated Hospital of Shanxi Medical University /ID# 276482
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- West China Hospital of Sichuan University /ID# 270244
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- Sichuan Province Cancer Hospital /ID# 269712
-
-
Yunnan
-
Kunming, Yunnan, Chine, 650106
- Recrutement
- Yunnan Province Cancer Hospital /ID# 272331
-
-
-
-
-
A Coruña, Espagne, 15006
- Recrutement
- Complejo Hospitalario Universitario A Coruna /ID# 271456
-
Alicante, Espagne, 03010
- Recrutement
- Hospital General Universitario de Alicante /ID# 271316
-
Barcelona, Espagne, 08036
- Recrutement
- Hospital Clinic de Barcelona /ID# 271452
-
Barcelona, Espagne, 08041
- Recrutement
- Hospital Santa Creu i Sant Pau /ID# 271311
-
Barcelona, Espagne, 08003
- Recrutement
- Hospital del Mar /ID# 271310
-
Málaga, Espagne, 29010
- Recrutement
- Hospital Universitario Virgen de la Victoria /ID# 271312
-
-
Cantabria
-
Santander, Cantabria, Espagne, 39008
- Recrutement
- Hospital Universitario Marques de Valdecilla /ID# 271314
-
-
Sevilla
-
Seville, Sevilla, Espagne, 41009
- Recrutement
- Hospital Universitario Virgen Macarena /ID# 271447
-
-
-
-
Gironde
-
Bordeaux, Gironde, France, 33000
- Recrutement
- Institut Bergonie /ID# 258377
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, France, 44800
- Recrutement
- CHU Nantes - Hopital Laennec /ID# 268475
-
Saint-Herblain, Loire-Atlantique, France, 44805
- Recrutement
- Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
-
-
Occitanie
-
Montpellier, Occitanie, France, 34070
- Recrutement
- Centre De Cancerologie Du Grand Montpellier /ID# 273724
-
-
Provence-Alpes-Côte d'Azur Region
-
Nice, Provence-Alpes-Côte d'Azur Region, France, 06189
- Recrutement
- Centre Antoine-Lacassagne /ID# 268486
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, France, 94805
- Recrutement
- Institut Gustave Roussy /ID# 258373
-
-
Île-de-France Region
-
Paris, Île-de-France Region, France, 75248
- Recrutement
- Institut Curie /ID# 271395
-
-
-
-
-
Bologna, Italie, 40138
- Recrutement
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
-
-
Forlì-Cesena
-
Meldola, Forlì-Cesena, Italie, 47014
- Recrutement
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
-
-
Milano
-
Milan, Milano, Italie, 20121
- Recrutement
- Istituto Europeo Di Oncologia /Id# 268670
-
-
Roma
-
Rome, Roma, Italie, 00144
- Recrutement
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
-
Rome, Roma, Italie, 00184
- Recrutement
- Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
-
-
The Marches
-
Ancona, The Marches, Italie, 60126
- Recrutement
- Azienda Ospedaliero Universitaria delle Marche /ID# 268667
-
-
Torino
-
Orbassano, Torino, Italie, 10043
- Recrutement
- Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
-
-
-
-
-
Nagasaki, Japon, 852-8501
- Recrutement
- Nagasaki University Hospital /ID# 273310
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 460-0001
- Recrutement
- NHO Nagoya Medical Center /ID# 272515
-
Nagoya, Aichi-ken, Japon, 464-8681
- Recrutement
- Aichi Cancer Center /ID# 271978
-
-
Aomori
-
Hirosaki, Aomori, Japon, 036-8563
- Recrutement
- Hirosaki University Hospital /ID# 274410
-
-
Kanagawa
-
Yokohama, Kanagawa, Japon, 221-0855
- Recrutement
- Yokohama Municipal Citizen's Hospital /ID# 271979
-
-
Kyoto
-
Kyoto, Kyoto, Japon, 606-8507
- Recrutement
- Kyoto University Hospital /ID# 272312
-
-
Niigata
-
Niigata, Niigata, Japon, 951-8520
- Recrutement
- Niigata University Medical and Dental Hospital /ID# 274448
-
-
Osaka
-
Takatsuki, Osaka, Japon, 569-8686
- Recrutement
- Osaka Medical And Pharmaceutical University Hospital /ID# 273309
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japon, 104-0045
- Recrutement
- National Cancer Center Hospital /ID# 273192
-
Koto-ku, Tokyo, Japon, 135-8550
- Recrutement
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Pologne, 20-090
- Recrutement
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Pologne, 15-540
- Recrutement
- Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Pologne, 80-214
- Recrutement
- Uniwersyteckie Centrum Kliniczne /ID# 272418
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Pologne, 25-734
- Recrutement
- Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Recrutement
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
-
-
-
-
-
Bucharest, Roumanie, 013975
- Recrutement
- MNT Healthcare Europe SRL /ID# 269075
-
Bucharest, Roumanie, 030171
- Recrutement
- Spitalul Clinic Coltea /ID# 268726
-
Sibiu, Roumanie, 550253
- Recrutement
- Clinica MedLife Polisano Sibiu /ID# 269078
-
-
Cluj
-
Cluj-Napoca, Cluj, Roumanie, 400080
- Recrutement
- S.C. Radiotherapy Center Cluj SRL /ID# 268729
-
Cluj-Napoca, Cluj, Roumanie, 400015
- Recrutement
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
-
Cluj-Napoca, Cluj, Roumanie, 400015
- Recrutement
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
-
-
-
-
-
Cardiff, Royaume-Uni, CF14 2TL
- Recrutement
- Velindre Cancer Centre /ID# 271840
-
-
Leicestershire
-
Leicester, Leicestershire, Royaume-Uni, LE1 5WW
- Recrutement
- University Hospitals of Leicester NHS Trust /ID# 276035
-
-
-
-
-
Changhua, Taïwan, 500
- Recrutement
- Changhua Christian Hospital /ID# 280139
-
Chiayi City, Taïwan, 62247
- Recrutement
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
-
Kaohsiung City, Taïwan, 807
- Recrutement
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
-
Kaohsiung City, Taïwan, 833
- Recrutement
- Kaohsiung Chang Gung Memorial Hospital /ID# 268138
-
Taipei, Taïwan, 114
- Recrutement
- Tri-Service General Hospital /ID# 269211
-
Taipei, Taïwan, 106
- Recrutement
- National Taiwan University Cancer Center (Ntucc) /ID# 271586
-
Taipei, Taïwan, 112
- Recrutement
- Taipei Veterans General Hospital /ID# 268787
-
Taoyuan City, Taïwan, 333
- Recrutement
- Linkou Chang Gung Memorial Hospital /ID# 268137
-
-
-
-
-
Adana, Turquie (Türkiye), 01140
- Recrutement
- Adana Medical Park Seyhan Hastanesi /ID# 272875
-
Ankara, Turquie (Türkiye), 06620
- Recrutement
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
-
Ankara, Turquie (Türkiye), 06680
- Recrutement
- Liv Hospital Ankara /ID# 272876
-
Ankara, Turquie (Türkiye), 06230
- Recrutement
- Hacettepe Universitesi Tip Fakultesi /ID# 280631
-
Denizli, Turquie (Türkiye), 20070
- Recrutement
- Pamukkale Universitesi /ID# 272893
-
Istanbul, Turquie (Türkiye), 34722
- Recrutement
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
-
Konya, Turquie (Türkiye), 42080
- Recrutement
- Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
-
Samsun, Turquie (Türkiye), 55139
- Recrutement
- Ondokuz Mayis Universitesi /ID# 272899
-
Samsun, Turquie (Türkiye), 55200
- Recrutement
- Samsun Medical Park Hastanesi /ID# 272880
-
-
Antalya
-
Ankara, Antalya, Turquie (Türkiye), 06010
- Recrutement
- Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
-
-
Sakarya
-
Adapazarı, Sakarya, Turquie (Türkiye), 54290
- Recrutement
- Sakarya Egitim ve Arastirma Hastanesi /ID# 272878
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Actif, ne recrute pas
- Mayo Clinic Hospital - Phoenix /ID# 272971
-
-
California
-
Fullerton, California, États-Unis, 92835
- Recrutement
- Providence - St. Jude Medical Center /ID# 271414
-
Oxnard, California, États-Unis, 93030
- Recrutement
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- UCLA - Santa Monica /ID# 271690
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- University Of Colorado - Anschutz Medical Campus /ID# 269069
-
Lone Tree, Colorado, États-Unis, 80124
- Recrutement
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Recrutement
- Mayo Clinic Hospital Jacksonville /ID# 275073
-
Orange City, Florida, États-Unis, 32763
- Recrutement
- Mid Florida Hematology And Oncology Center /ID# 273777
-
-
Illinois
-
Hinsdale, Illinois, États-Unis, 60521
- Recrutement
- Hope And Healing Cancer Services /ID# 276223
-
Contact:
- Site Coordinator
- Numéro de téléphone: 6305600121
-
-
Indiana
-
Fort Wayne, Indiana, États-Unis, 46845
- Recrutement
- Parkview Comprehensive Cancer Center /ID# 271879
-
Indianapolis, Indiana, États-Unis, 46202
- Complété
- Community Health Network /ID# 273437
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66210
- Recrutement
- Kansas City Cancer Center /ID# 273679
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana-Farber Cancer Institute /ID# 278417
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Hospital - Detroit /ID# 271642
-
-
Minnesota
-
Duluth, Minnesota, États-Unis, 55805
- Recrutement
- St. Luke'S /ID# 273344
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic-Rochester /ID# 274512
-
-
New Jersey
-
East Brunswick, New Jersey, États-Unis, 08816-4096
- Recrutement
- Astera Cancer Care /ID# 271915
-
-
New York
-
Shirley, New York, États-Unis, 11967
- Recrutement
- New York Cancer And Blood Specialists - Shirley /ID# 272547
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Complété
- University Hospitals Cleveland Medical Center /ID# 271726
-
Columbus, Ohio, États-Unis, 43219
- Recrutement
- The Mark H Zangmeister Center /ID# 272502
-
-
Pennsylvania
-
Easton, Pennsylvania, États-Unis, 18045
- Recrutement
- Spoknwrd Clinical Trials /ID# 273776
-
Contact:
- Site Coordinator
- Numéro de téléphone: 610-813-2087
-
-
Texas
-
Houston, Texas, États-Unis, 77090
- Complété
- Millennium Physicians /ID# 271717
-
Lubbock, Texas, États-Unis, 79410-1121
- Recrutement
- Joe Arrington Cancer Research /ID# 272776
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Recrutement
- Huntsman Cancer Institute /ID# 271686
-
-
Virginia
-
Leesburg, Virginia, États-Unis, 20176
- Recrutement
- Virgnia Cancer Specialists /ID# 269633
-
-
Washington
-
Olympia, Washington, États-Unis, 98506
- Recrutement
- Vista Oncology - East Olympia /ID# 275438
-
Tacoma, Washington, États-Unis, 98405
- Recrutement
- Northwest Medical Specialties Tacoma /ID# 270469
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- Must have documented programmed death ligand 1 (PD-L1) status.
- For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- Must have adequate organ function.
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1: Telisotuzumab Adizutecan + Budigalimab
Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Autres noms:
IV Infusion
Autres noms:
|
|
Expérimental: Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Autres noms:
IV Injection IV Infusion |
|
Expérimental: Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Autres noms:
IV Injection IV Infusion |
|
Expérimental: Part 2: Standard of Care
Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration. |
IV Infusion IV Infusion IV Injection IV Infusion IV Infusion |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Délai: Up to Approximately 84 Days
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to Approximately 84 Days
|
|
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Délai: Up to Approximately 33 Months
|
OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to Approximately 33 Months
|
|
Number of Participants with Adverse Events (AE)s
Délai: Up to Approximately 33 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 33 Months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1 and Part 2: PFS as Assessed by Investigator
Délai: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DOR as Assessed by Investigator
Délai: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DC as Assessed by Investigator
Délai: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: Overall Survival (OS)
Délai: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
Délai: Up to Approximately 33 Months
|
OR is defined as confirmed CR or confirmed PR based on RECIST v1.1. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: PFS
Délai: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: OS
Délai: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DOR
Délai: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DC
Délai: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1. |
Up to Approximately 33 Months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Carcinome bronchique
- Tumeurs bronchiques
- Carcinome pulmonaire non à petites cellules
- Acides aminés, peptides et protéines
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Complexes de coordination
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Acides aminés, acides
- Acides aminés
- Acides aminés, dicarboxylique
- Composés en platine
- Pémétrexed
- Carboplatine
- Cisplatine
- pembrolizumab
- bugalimab
Autres numéros d'identification d'étude
- M24-536
- 2024-514465-18 (Autre identifiant: EU CT)
- 2024-514465-18-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Délai de partage IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critères d'accès au partage IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .